PLIANT THERAPEUTICS, INC.PLRXEarnings & Financial Report
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for fibrotic diseases. Its pipeline includes candidate treatments for idiopathic pulmonary fibrosis, liver fibrosis and other chronic fibrotic conditions, with primary U.S. operations focused on addressing global unmet patient medical needs.
PLRX Q4 FY2024 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-53.3M
Net Profit
$-49.7M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.82
PLIANT THERAPEUTICS, INC. Q4 FY2024 Financial Summary
PLIANT THERAPEUTICS, INC. reported revenue of $0 for Q4 FY2024, with a net profit of $-49.7M (down 21.0% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-49.7M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2024 |
PLIANT THERAPEUTICS, INC. Annual Revenue by Year
PLIANT THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
PLIANT THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
PLIANT THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $0 | — | $-49.7M | N/A |
| Q3 FY2024 | $0 | — | $-57.8M | N/A |
| Q2 FY2024 | $0 | — | $-55.9M | N/A |
| Q1 FY2024 | $0 | — | $-47.0M | N/A |
| Q4 FY2023 | $0 | — | $-41.1M | N/A |
| Q3 FY2023 | $0 | — | $-41.5M | N/A |
| Q2 FY2023 | $248.0K | -95.0% | $-41.2M | -16609.7% |
| Q1 FY2023 | $1.3M | +6.6% | $-37.5M | -2818.9% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $248000 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | 6.6% | -95.0% | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $597.9M | $574.9M | $540.5M | $512.2M | $521.6M | $483.7M | $445.7M | $396.9M |
| Liabilities | $36.0M | $41.8M | $37.4M | $38.6M | $84.3M | $91.1M | $99.8M | $92.9M |
| Equity | $561.9M | $533.1M | $503.0M | $473.6M | $437.3M | $392.7M | $345.8M | $304.1M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-30.3M | $-24.8M | $-36.2M | $-25.1M | $-30.3M | $-45.3M | $-32.3M | $-47.7M |